Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions

Background Large deletions of the NF1 gene region occur in ∼5% of patients with neurofibromatosis type-1 (NF1) and are associated with particularly severe manifestations of the disease. However, until now, the genotype–phenotype relationship has not been comprehensively studied in patients harbouring large NF1 gene deletions of comparable extent (giving rise to haploinsufficiency of the same genes). Method We have performed the most comprehensive clinical/neuropsychological characterisation so far undertaken in NF1 deletion patients, involving 29 patients with precisely determined type-1 NF1 (1.4 Mb) deletions. Results Novel clinical features found to be associated with type-1 NF1 deletions included pes cavus (17% of patients), bone cysts (50%), attention deficit (73%), muscular hypotonia (45%) and speech difficulties (48%). Type-1 NF1 deletions were found to be disproportionately associated with facial dysmorphic features (90% of patients), tall stature (46%), large hands and feet (46%), scoliosis (43%), joint hyperflexibility (72%), delayed cognitive development and/or learning disabilities (93%) and mental retardation (IQ<70; 38%), as compared with the general NF1 patient population. Significantly increased frequencies (relative to the general NF1 population) of plexiform neurofibromas (76%), subcutaneous neurofibromas (76%), spinal neurofibromas (64%) and MPNSTs (21%) were also noted in the type-1 deletion patients. Further, 50% of the adult patients exhibited a very high burden of cutaneous neurofibromas (N≥1000). Conclusion These findings emphasise the importance of deletion analysis in NF1 since frequent monitoring of tumour presence and growth could potentiate early surgical intervention thereby improving patient survival.

[1]  G. Mortier,et al.  Speech disorders in neurofibromatosis type 1: a sample survey. , 2010, International journal of language & communication disorders.

[2]  R. Siebert,et al.  Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene , 2004, Human mutation.

[3]  N. Lindor,et al.  Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature , 2005, Journal of Medical Genetics.

[4]  S. Ozonoff,et al.  Cognitive impairment in neurofibromatosis type 1. , 1999, American journal of medical genetics.

[5]  W. Burke,et al.  Large de novo DNA deletion in a patient with sporadic neurofibromatosis 1, mental retardation, and dysmorphism. , 1992, Journal of medical genetics.

[6]  B. Dallapiccola,et al.  Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification , 2007, Journal of Medical Genetics.

[7]  O. Aaltonen,et al.  Speech characteristics in neurofibromatosis type 1 , 2010, American journal of medical genetics. Part A.

[8]  D. Cooper,et al.  Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes? , 2008, Journal of Medical Genetics.

[9]  A. Dachman,et al.  CT imaging in adults with neurofibromatosis‐1 , 1998, Neurology.

[10]  M. Stephens,et al.  Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion , 2006, Nature Genetics.

[11]  S. Berry Neurofibromatosis: Phenotype, Natural History and Pathogenesis, 2nd Edition , 1993 .

[12]  B. McManus,et al.  Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force , 2002, Genetics in Medicine.

[13]  K. North,et al.  Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1 , 2003, Neurology.

[14]  J. Zeller,et al.  Association between benign and malignant peripheral nerve sheath tumors in NF1 , 2005, Neurology.

[15]  D. Cooper,et al.  Evaluation of genotype-phenotype correlations in neurofibromatosis type 1 , 2003, Journal of medical genetics.

[16]  D. Louis,et al.  Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. , 1997, Annals of neurology.

[17]  E. Legius,et al.  Intelligence in individuals with a neurofibromatosis type 1 microdeletion , 2004, American journal of medical genetics. Part A.

[18]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.

[19]  D. Louis,et al.  Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the nf1 optic pathway glioma task force , 1997 .

[20]  R. Hughes,et al.  MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[21]  R. Bryan,et al.  Neurofibromatosis type 1: the evolution of deep gray and white matter MR abnormalities. , 1994, AJNR. American journal of neuroradiology.

[22]  D. Gutmann,et al.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. , 2002, Cancer research.

[23]  R. Tenconi,et al.  Mental retardation and cardiovascular malformations in NF 1 microdeleted patients point to candidate genes in 17 q 11 . 2 * , 2004 .

[24]  H. Kehrer-Sawatzki,et al.  High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene. , 2004, American journal of human genetics.

[25]  M. Dorschner,et al.  Recombination hotspot in NF1 microdeletion patients. , 2001, Human molecular genetics.

[26]  S. Pilotti,et al.  Elevated risk for MPNST in NF1 microdeletion patients. , 2003, American journal of human genetics.

[27]  K. North,et al.  T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[28]  L. Bolund,et al.  Identification of novel deletion breakpoints bordered by segmental duplications in the NF1 locus using high resolution array-CGH , 2005, Journal of Medical Genetics.

[29]  M. Denckla,et al.  Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. , 1997, Neurology.

[30]  D. Horn,et al.  Childhood overgrowth in patients with common NF1 microdeletions , 2005, European Journal of Human Genetics.

[31]  Kathryn N North,et al.  The nature and frequency of cognitive deficits in children with neurofibromatosis type 1 , 2005, Neurology.

[32]  M. Weaver,et al.  NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. , 2000, Human molecular genetics.

[33]  H. Hameister,et al.  Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. , 2001, American journal of human genetics.

[34]  M Super,et al.  A clinical study of type 1 neurofibromatosis in north west England , 1999, Journal of medical genetics.

[35]  J. Tonsgard,et al.  Do NF1 gene deletions result in a characteristic phenotype? , 1997, American journal of medical genetics.

[36]  V. M. Riccardi,et al.  von Recklinghausen Neurofibromatosis , 1981 .

[37]  Jan M Friedman,et al.  Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. , 2008, Neuro-oncology.

[38]  A. Paller Neurofibromatosis: Phenotype, Natural History, and Pathogenesis , 1993 .

[39]  B. Korf,et al.  Structural anomalies revealed by neuroimaging studies in the brains of patients with neurofibromatosis type 1 and large deletions , 1999, Genetics in Medicine.

[40]  E. Zackai,et al.  Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. , 1995, Radiology.

[41]  K. North Neurofibromatosis Type 1: Review of the First 200 Patients in an Australian Clinic , 1993, Journal of child neurology.

[42]  L. Kluwe,et al.  Treatment of ADHD in neurofibromatosis type 1 , 2002, Developmental medicine and child neurology.

[43]  M. Brooks Skeletal System , 2011, Indian Journal of Nuclear Medicine : IJNM : The Official Journal of the Society of Nuclear Medicine, India.

[44]  H. Kehrer-Sawatzki,et al.  Spectrum of single‐ and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients , 2006, Genes, chromosomes & cancer.

[45]  K. Khosrotehrani,et al.  Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients , 2005, American journal of medical genetics. Part A.

[46]  C. Romano,et al.  Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. , 2000, American journal of medical genetics.

[47]  R. Packer,et al.  Neurocognitive dysfunction in children with neurofibromatosis type 1 , 2003, Current neurology and neuroscience reports.

[48]  D. Evans,et al.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 , 2006, Journal of Medical Genetics.

[49]  Eugene C. Lai,et al.  Evaluation and management , 2011 .

[50]  R. Ferner,et al.  Intellectual impairment in neurofibromatosis 1 , 1996, Journal of the Neurological Sciences.

[51]  L. Bernardini,et al.  Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification , 2007, Journal of Medical Genetics.

[52]  T. Slamovits Von Recklinghausen neurofibromatosis: II. Incidence of optic gliomata. , 1985, Ophthalmology.

[53]  S. Huson,et al.  Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales , 1988 .

[54]  W. H. Dowdeswell Evaluation and management , 1978 .

[55]  D. Cooper,et al.  Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous recombination hotspots and an apparent preference for female mitotic recombination. , 2007, American journal of human genetics.

[56]  M. Dorschner,et al.  Genomic context of paralogous recombination hotspots mediating recurrent NF1 region microdeletion , 2004, Genes, chromosomes & cancer.

[57]  R. Tenconi,et al.  Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2 , 2004, Journal of Medical Genetics.

[58]  J. Towbin,et al.  Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. , 2000, American journal of medical genetics.

[59]  J. Soulier,et al.  Technical Advance Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH , 2009 .

[60]  H. Kehrer-Sawatzki,et al.  Absence of cutaneous neurofibromas in an NF1 patient with an atypical deletion partially overlapping the common 1.4 Mb microdeleted region , 2008, American journal of medical genetics. Part A.

[61]  G. Di Salvo,et al.  Cardiac abnormalities detected by Doppler imaging in patients with neurofibromatosis type 1. , 2001, The American journal of cardiology.

[62]  R. Hughes,et al.  The Neurofibromatoses : a pathogenetic and clinical overview , 1994 .